NasdaqGS:GILD - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	31,560	9,628	13,193	12,246	22
12/31/2026	30,120	8,946	12,658	11,602	27
12/31/2025	29,210	8,283	10,767	10,533	25
9/30/2025	29,087	8,110	9,162	9,667	N/A
6/30/2025	28,863	6,311	9,369	9,868	N/A
3/31/2025	28,735	5,965	9,844	10,366	N/A
12/31/2024	28,754	480	10,305	10,828	N/A
9/30/2024	28,299	126	9,431	10,022	N/A
6/30/2024	27,805	1,054	6,896	7,468	N/A
3/31/2024	27,450	485	7,900	8,481	N/A
12/31/2023	27,116	5,665	7,421	8,006	N/A
9/30/2023	27,391	5,876	7,853	8,404	N/A
6/30/2023	27,382	5,484	8,926	9,512	N/A
3/31/2023	27,043	5,583	8,386	8,976	N/A
12/31/2022	27,281	4,592	8,344	9,072	N/A
9/30/2022	27,136	3,334	9,007	9,710	N/A
6/30/2022	27,515	4,137	9,415	10,100	N/A
3/31/2022	27,472	4,515	9,953	10,614	N/A
12/31/2021	27,305	6,225	10,805	11,384	N/A
9/30/2021	27,482	7,394	9,491	10,095	N/A
6/30/2021	26,638	5,162	8,472	9,092	N/A
3/31/2021	25,564	301	8,698	9,342	N/A
12/31/2020	24,689	123	7,518	8,168	N/A
9/30/2020	23,147	1,268	8,160	8,832	N/A
6/30/2020	22,174	-257	8,510	9,227	N/A
3/31/2020	22,716	4,962	8,244	9,003	N/A
12/31/2019	22,449	5,386	8,319	9,144	N/A
9/30/2019	22,365	2,693	8,039	8,909	N/A
6/30/2019	22,357	5,955	N/A	8,476	N/A
3/31/2019	22,320	5,892	N/A	7,707	N/A
12/31/2018	22,127	5,455	N/A	8,400	N/A
9/30/2018	22,281	1,587	N/A	8,808	N/A
6/30/2018	23,197	2,208	N/A	9,290	N/A
3/31/2018	24,690	3,464	N/A	11,243	N/A
12/31/2017	26,107	4,628	N/A	11,898	N/A
9/30/2017	27,478	11,601	N/A	12,684	N/A
6/30/2017	28,466	12,213	N/A	14,383	N/A
3/31/2017	29,101	12,637	N/A	15,842	N/A
12/31/2016	30,390	13,501	N/A	17,047	N/A
9/30/2016	31,576	15,076	N/A	18,382	N/A
6/30/2016	32,371	16,346	N/A	18,085	N/A
3/31/2016	32,839	17,341	N/A	18,758	N/A
12/31/2015	32,639	18,108	N/A	21,250	N/A
9/30/2015	31,447	16,912	N/A	18,476	N/A
6/30/2015	29,194	15,043	N/A	18,424	N/A
3/31/2015	27,485	14,207	N/A	16,951	N/A
12/31/2014	24,890	12,101	N/A	12,818	N/A

애널리스트 향후 성장 전망

수입 대 저축률: GILD 의 연간 예상 수익 증가율(7.4%)이 saving rate(3.3%)보다 높습니다.

수익 vs 시장: GILD 의 연간 수익(7.4%)이 US 시장(16.2%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: GILD 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: GILD 의 수익(연간 3.8%)이 US 시장(연간 10.7%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: GILD 의 수익(연간 3.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: GILD의 자본 수익률은 3년 후 34.3%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/24 14:30
종가	2025/12/24 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Gilead Sciences, Inc.는 67명의 분석가가 다루고 있습니다. 이 중 27명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
David Toung	Argus Research Company
Brian Skorney	Baird
James Birchenough	Barclays

Gilead Sciences 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Consensus EPS estimates increase by 15%

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2025

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2025

Consensus EPS estimates fall by 27%

Consensus EPS estimates fall by 36%

Price target increased by 7.6% to US$94.62

Recent updates

Gilead Sciences, Inc. Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Effective December 18, 2025

Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ARTISTRY-2 Trial

Upcoming dividend of US$0.79 per share

Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength

Deborah H. Telman to No Longer Serve as Executive Vice President, Corporate Affairs and General Counsel of Gilead Sciences, Inc. as of December 5, 2025

Gilead Sciences, Inc. Joins Partners for Delivery of First Shipments of Breakthrough Twice-Yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

Executive VP of Corporate Affairs exercised options and sold US$3.1m worth of stock

Gilead Sciences, Inc.'s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ART-1 Trial

Gilead Sciences, Inc. Provides Update on Phase 3 ASCENT-07 Study

Consensus EPS estimates increase by 15%

Third quarter dividend of US$0.79 announced

Gilead Sciences, Inc. announces Quarterly dividend, payable on December 30, 2025

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2025

Gilead Sciences, Inc. to Showcase Interim Long-Term Efficacy Data for Livdelzi (Seladelpar) in Primary Biliary Cholangitis (Pbc) and Investigational Bulevirtide in Chronic Hepatitis Delta

Gilead Sciences, Inc. Receives Health Canada Approval for the Treatment of Primary Biliary Cholangitis

Gilead Sciences, Inc. to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

Gilead Presents New Hiv Research Data At EACS 2025 – Driving Scientific Innovation in Treatment and Prevention

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care with New Data At Esmo 2025

Gilead Sciences, Inc. to Report Q3, 2025 Results on Oct 30, 2025

Upcoming dividend of US$0.79 per share

Gilead Sciences, Inc. Announces European Commission Authorizes Twice-Y Early Yeytuo (Lenacapavir) for HIV Prevention

Chief Commercial Officer notifies of intention to sell stock

Second quarter dividend of US$0.79 announced

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Gilead Sciences, Inc. (NasdaqGS:GILD) announces an Equity Buyback for $6,000 million worth of its shares.

Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?

Gilead Receives Positive CHMP Opinions Under Accelerated Review from European Medicines Agency for Twice-Yearly HIV PrEP Option in the European Union

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for Hiv Prevention At Ias 2025

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approves Yeztugo (Lanacapavir) as Pre-Exposure Prophylaxis

Upcoming dividend of US$0.79 per share

Gilead Sciences, Inc. Announces Trodelvy Plus Keytruda®? Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

Chief Commercial Officer notifies of intention to sell stock

Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-03 Study of Trodelvy

Statutory Profit Doesn't Reflect How Good Gilead Sciences' (NASDAQ:GILD) Earnings Are

Gilead's Livdelzi (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented At EASL 2025

Gilead Sciences, Inc. to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

First quarter dividend of US$0.79 announced

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Gilead Sciences Q1 Earnings Review: HIV Division Masks Underperformance

Gilead Sciences, Inc. Declares Quarterly Dividend for the Second Quarter of 2025, Payable on June 27, 2025

Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-04/KeyNOTE-D19 Study

Revenues Working Against Gilead Sciences, Inc.'s (NASDAQ:GILD) Share Price

Gilead Sciences, Inc. to Report Q1, 2025 Results on Apr 24, 2025

New HIV, Livdelzi And CAR T Options Will Expand Reach

Gilead Sciences, Inc., Annual General Meeting, May 07, 2025

Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally

Chairman & CEO exercised options and sold US$1.4m worth of stock

Gilead Sciences, Inc. Presents New HIV Treatment and Cure Research Data At CROI 2025, Including an Investigational Long-Acting, Twice-Y Early Therapy Option

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

Gilead Sciences, Inc. Presents the First Data from Its Ongoing Phase 1 Study Investigating Two Novel, Once-Yearly Formulations of Lenacapavir

Upcoming dividend of US$0.79 per share

Why Gilead Sciences Remains A Buy After A 40% Rally

European Medicines Agency Validates Gilead's Marketing Authorization Application and Eu-Medicines for All Application for Twice-Yearly Lenacapavir for Hiv Prevention

Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Gilead Sciences, Inc. Announces U.S. FDA Acceptance of Its New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

Chief Financial Officer exercised options and sold US$4.8m worth of stock

Fourth quarter dividend increased to US$0.79

New minor risk - Financial position

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2025

Gilead Sciences: Diversification Strategy Not Derisked Enough Yet

Gilead Sciences (NASDAQ:GILD) Could Easily Take On More Debt

Gilead: Strong Sales Growth Remains With Veklury And Beyond

Gilead Sciences, Inc. to Report Q4, 2024 Results on Feb 11, 2025

Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise

Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure

Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

Consensus EPS estimates fall by 27%